C22H18F3N5O2S2
Neat
505.53
Desmethyl dabrafenib; 1195765-47-9; Dabrafenib metabolite M8; 3EHQ1EWE0D; GSK2167542; GSK-2167542; N-[3-[5-(2-aminopyrimidin-4-yl)-2-propan-2-yl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2, 6-difluorobenzenesulfonamide; Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1-methylethyl)-4-thiazolyl)-2-fluorophenyl)-2, 6-difluoro-; N-(3-(5-(2-Aminopyrimidin-4-yl)-2-isopropylthiazol-4-yl)-2-fluorophenyl)-2, 6-difluorobenzenesulfonamide; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1-methylethyl)-4-thiazolyl]-2-fluorophenyl]-2, 6-difluorobenzenesulfonamide; UNII-3EHQ1EWE0D; GSK 2167542; starbld0012062; orb654525; SCHEMBL2192083; MQEHPCURISZMGR-UHFFFAOYSA-N; DTXSID901108690; Q27257115; N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1-methylethyl)-1, 3-thiazol-4-yl]-2-fluorophenyl}-2 and 6-difluorobenzenesulfonamide
N-[3-[5-(2-aminopyrimidin-4-yl)-2-propan-2-yl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2 and 6-difluorobenzenesulfonamide
InChI=1S/C22H18F3N5O2S2/c1-11(2)21-29-18(19(33-21)16-9-10-27-22(26)28-16)12-5-3-8-15(17(12)25)30-34(31,32)20-13(23)6-4-7-14(20)24/h3-11,30H,1-2H3,(H2,26,27,28)